|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2000-6-6
|
|
pubmed:abstractText |
The goal of this study was to determine the maximally tolerated doses (MTDs) of carboplatin, paclitaxel (Taxol), etoposide, and cyclophosphamide (CTEC) with granulocyte-colony stimulating factor (G-CSF, Filgrastim) support as first-line chemotherapy in women with advanced epithelial ovarian cancer (EOC).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0090-8258
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2000 Academic Press.
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
77
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
271-7
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:10785477-Adult,
pubmed-meshheading:10785477-Aged,
pubmed-meshheading:10785477-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10785477-Carboplatin,
pubmed-meshheading:10785477-Carcinoma,
pubmed-meshheading:10785477-Cyclophosphamide,
pubmed-meshheading:10785477-Disease-Free Survival,
pubmed-meshheading:10785477-Dose-Response Relationship, Drug,
pubmed-meshheading:10785477-Etoposide,
pubmed-meshheading:10785477-Female,
pubmed-meshheading:10785477-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:10785477-Humans,
pubmed-meshheading:10785477-Middle Aged,
pubmed-meshheading:10785477-Neutropenia,
pubmed-meshheading:10785477-Ovarian Neoplasms,
pubmed-meshheading:10785477-Paclitaxel,
pubmed-meshheading:10785477-Taxoids,
pubmed-meshheading:10785477-Thrombocytopenia,
pubmed-meshheading:10785477-Treatment Outcome
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
|
|
pubmed:affiliation |
Program in Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase I
|
